Pharmaceutical companies have prioritized profits over safety, with lawsuits revealing hidden risks and regulatory failures, ...

President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ‌supply chains and ...

A remarkable number of biopharma companies, under the gun to get their research and products to market quicker, aren't happy with design-build and design-build-bid methods of construction project ...

Building out a robust competency-based training system requires more upfront planning and concentrated effort. It will allow ...

The pharmaceutical industry is navigating one of its most disruptive periods in recent memory, according to Anthony Lakavage, ...

The biopharma industry has spent much of this year grappling with fast-moving changes related to the Trump administration's trade policies. On Thursday, without warning, came another jolt. “Starting ...

Join us for Open Doors – As the biopharma landscape accelerates through scientific innovation, economic pressures, and evolving global dynamics, where should companies place their bets to drive ...

AI is already helping the biopharmaceutical industry to optimize its manufacturing activities, according to IFPMA.

The U.S. pharmaceutical market is at a critical inflection point in early 2026. For decades, the industry has operated within a framework that, while fostering significant innovation, has also ...

The 2026 Government Work Report identified biopharmaceuticals as an emerging pillar industry for the first time, placing it ...

Event driven snapshot of ArriVent BioPharma ArriVent BioPharma (AVBP) shares recently moved following investor attention on its clinical stage oncology pipeline and ongoing trials. This has prompted ...

– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation ...